Guidance ledger · Q4 FY26

Dr Lal PathLabs Ltd DRLAL

3 revisions on record · 0 lowered · 2 raised — the strikethrough is what management used to say

directional guidance only · shifted across quarters

Holding view → · latest concall · The pulse

→ narrowed FY26 revenue growth guidance Q1 FY26 → Q4 FY26

~~11%-12%~~ → 11%-12% (maintained all year; delivered 12.2%)

“We will stay with our 11%-12% revenue growth projection.”

↑ raised FY27 revenue growth guidance Q2 FY26 → Q4 FY26

~~13%-14% long-term CAGR (aspirational)~~ → early to mid-teens (13%-15%) FY27 guidance

“When we say early to mid-teens, I am talking of a range it could be between 13%-15%”

↑ raised FY26 EBITDA margin guidance Q1 FY26 → Q2 FY26

~~slightly better than earlier ~27% projection~~ → 27%-28%

“this year, we are estimating that between 27% to 28% margins, we are confident to maintain.”

Method. Revisions come from management's own stated numbers, compared quarter over quarter across the covered concalls; each carries the verbatim quote. “No revisions” can also mean guidance too vague to pin down — see the posture chip above. Not investment advice.